Investor Relations
Create continuously growing value for investors
Press Releases
Sihuan Pharmaceutical’s Gabapentin Capsules was Granted Drug Production Approval,the Third Company Obtained Approval in China
2020-10-28
Sihuan Pharmaceutical Invests in Phase I Fund of Ascendum Capital Life Technology to Expand its Strategy in Development of Innovative Drugs
2020-10-28
SDIC leads the investment of Xuanzhu Biopharmaceutical with RMB 800 million, promoting innovation and R&D
2020-10-28
Sihuan Pharmaceutical Announces 2020 Interim Results Revenue and Profit Attributable to Owners of the Company from Continuing Operations are RMB1,054.5 million and RMB170.5 million, respectively
2020-08-25
Announcements and Circulars
MOREResults Presentation
MORERecommended Reading